Zomedica CORP

Zomedica Corp. held its annual shareholder meeting on June 10, 2026, where directors were elected, auditors ratified, and bylaws amended, but executive compensation failed to gain advisory approval.

Zomedica achieved record first-quarter revenue of $8.8 million, marking 35% year-over-year growth and its 21st consecutive quarter of record revenue.

Zomedica Corp. announced record fourth-quarter revenue of $10.5 million and full-year 2025 revenue of $32.0 million, marking 17% annual growth and its 20th consecutive quarter of year-over-year revenue increase.

Zomedica Corp. reported its highest-ever quarterly revenue of $8.1 million, a 16% increase year-over-year, driven by strong diagnostic and new development services growth, alongside a 67% gross margin and $54.4 million in liquidity.

Zomedica Corp. announced strong second quarter 2025 financial results, with revenue increasing 14% year-over-year to $7.0 million, driven by robust growth in diagnostic and therapeutic product sales.

Zomedica Corp. shareholders approved the election of directors and ratification of auditors but delivered a non-binding advisory vote against executive compensation at their annual meeting on June 10, 2025.

Zomedica Corp. reported increased revenue for Q3 2025 and the nine months ended September 30, 2025, despite significant impairment charges totaling $55.8 million.

Zomedica Corp. reported increased revenue for Q2 2025, but a significant impairment charge in Q1 led to a higher net loss for the six-month period.

Zomedica Corp. saw a modest revenue increase in Q1 2025 but reported a substantial net loss due to significant impairment charges related to goodwill and intangible assets.

Zomedica Corp. saw a 10% increase in revenue year-over-year for Q3 2024, but reported a significant net loss due to impairment charges.

Zomedica Corp. saw a slight increase in revenue for Q2 2024, but reported a significant net loss due to a substantial goodwill impairment charge.

Zomedica Corp. saw a 14% increase in revenue in the first quarter of 2024 compared to the same period last year, but also experienced a larger net loss.

Zomedica Corp. reported a 17% increase in revenue to $32.03 million for fiscal year 2025, alongside a significant net loss of $81.86 million driven by impairment charges following its delisting from NYSE American.

Zomedica Corp.'s 2024 10-K filing reveals a company in transition, navigating delisting from NYSE American while focusing on strategic acquisitions and product commercialization to drive future growth.

Zomedica Corp.'s 10-K filing highlights a year of strategic acquisitions and revenue growth, alongside ongoing losses and a focus on expanding its veterinary product portfolio.

Zomedica Corp. reports a significant purchase of common stock by its Sr. Vice President, Sales, Kevin Klass.

Zomedica Corp. director Johnny D. Powers reported the acquisition of 100,000 shares of common stock on May 18, 2026, at a price of $0.103 per share.

Zomedica Corp. reports insider transactions by Sr. Vice President, Sales, Kevin Klass, involving the acquisition of common stock.

Zomedica Corp. director Johnny D. Powers reported the acquisition of 108,871 shares on May 8, 2026, and an additional 391,129 shares on May 11, 2026.

Zomedica Corp. CEO Larry C. Heaton II purchased 250,000 shares of common stock at $0.11 per share.

Director Sean Whelan received 1,975,033 stock appreciation rights at a $0.10 base price, first exercisable on 2026-11-16 and expiring on 2035-11-16.

Zomedica Corp. has issued a final reminder to its shareholders to submit their proxy votes by June 8, 2025, for the upcoming Annual Shareholder Meeting on June 10, 2025.

Zomedica Corp. has issued a reminder to its shareholders to submit their proxies by June 8, 2025, for the upcoming virtual Annual Shareholder Meeting on June 10, 2025.

Zomedica Corp. has issued a proxy statement to shareholders, encouraging votes for its upcoming virtual Annual Meeting on June 10, 2025, while highlighting recent Q1 financial results and an upcoming webinar on its PulseVet Shock Wave System.

Zomedica Corp. issues a supplement to its definitive proxy statement to correct an omission of executive compensation details for Tony Blair and Karen DeHaan-Fullerton for the year ended December 31, 2023.

A preliminary proxy statement has been filed, indicating upcoming corporate actions requiring shareholder input.

Zomedica Corp. will hold its Annual Meeting of Shareholders on June 10, 2025, to vote on director elections, auditor ratification, and executive compensation.